Dice Therapeutics
San Francisco
About Dice Therapeutics
DICE Therapeutics is a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. DICE is initially focused on developing oral therapeutics against well-validated targets in immunology, with the goal of achieving comparable potency to their systemic biologic counterparts, which have demonstrated the greatest therapeutic benefit to date in these disease areas. The Company’s DELSCAPE platform is designed to discover selective oral small molecules with the potential to modulate protein-protein interactions (PPIs) as effectively as systemic biologics. DICE’s lead therapeutic candidate, S011806, is an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17 (IL-17), which is a validated drug target implicated in a variety of immunology indications. DICE is also developing oral therapeutic candidates targeting ╬▒4ß7 integrin and ╬▒Vß1/╬▒Vß6 integrin for the treatment of inflammatory bowel disease and idiopathic pulmonary fibrosis, respectively.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Delisted
- Employees: 51 – 100
- Estimated revenue: $10K – $50K
- Total funding: $532.4M
- Funding stage: M&A
- Last round: Post-IPO Equity (Oct 2022)
- Ticker: nasdaq:DICE
- Website: dicetherapeutics.com
- Phone: (650) 566-1402
Industries & Categories
Biotechnology, Medical, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/dice-therapeutics-68453 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.